Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
$13.17
+0.4%
$11.51
$6.64
$35.52
$12.87M1.87479,845 shs17,400 shs
Avinger, Inc. stock logo
AVGR
Avinger
$3.80
-1.0%
$3.46
$2.50
$18.00
$6.09M1.2243,012 shs10,221 shs
Dynatronics Co. stock logo
DYNT
Dynatronics
$0.45
-8.2%
$0.47
$0.37
$1.44
$2.20M0.41349,405 shs56,386 shs
LLIT
Lianluo Smart
$0.87
+3.6%
$9.91
$2.76
$17.14
$1.93M0.161.04 million shs725,862 shs
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
$0.00
$0.00
$0.01
N/AN/AN/AN/A
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
0.00%0.00%0.00%0.00%0.00%
Avinger, Inc. stock logo
AVGR
Avinger
+4.34%-0.26%+24.27%+48.84%-40.47%
Dynatronics Co. stock logo
DYNT
Dynatronics
-3.03%-14.89%+7.30%-7.59%-64.26%
LLIT
Lianluo Smart
0.00%+3.03%-4.71%+17.34%-23.58%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
1.9353 of 5 stars
3.55.00.00.00.00.80.6
Dynatronics Co. stock logo
DYNT
Dynatronics
0.7899 of 5 stars
3.03.00.00.00.60.00.6
LLIT
Lianluo Smart
N/AN/AN/AN/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
3.00
Buy$5.0031.58% Upside
Dynatronics Co. stock logo
DYNT
Dynatronics
2.00
Hold$3.80743.13% Upside
LLIT
Lianluo Smart
N/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/A

Current Analyst Ratings

Latest AVGR, DYNT, APOP, MDIT, and LLIT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/21/2024
Avinger, Inc. stock logo
AVGR
Avinger
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/A$4.77 per shareN/A
Avinger, Inc. stock logo
AVGR
Avinger
$7.65M0.79N/AN/A($4.53) per share-0.84
Dynatronics Co. stock logo
DYNT
Dynatronics
$40.61M0.05N/AN/A$2.19 per share0.21
LLIT
Lianluo Smart
$380K5.08N/AN/A($0.59) per share-1.48
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
-$5.62MN/A0.00N/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
-$18.32M-$26.34N/AN/AN/A-239.41%N/A-106.16%5/8/2024 (Estimated)
Dynatronics Co. stock logo
DYNT
Dynatronics
-$4.97M-$1.38N/AN/A-14.13%-54.88%-16.14%5/9/2024 (Estimated)
LLIT
Lianluo Smart
-$4.45MN/A0.00N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest AVGR, DYNT, APOP, MDIT, and LLIT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/20/2024Q4 2023
Avinger, Inc. stock logo
AVGR
Avinger
$0.64-$3.93-$4.57-$3.93$2.52 million$1.91 million
2/7/2024Q2 2024
Dynatronics Co. stock logo
DYNT
Dynatronics
N/A-$0.27-$0.27-$0.27N/A$8.15 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/AN/AN/AN/AN/A
Avinger, Inc. stock logo
AVGR
Avinger
N/AN/AN/AN/AN/A
Dynatronics Co. stock logo
DYNT
Dynatronics
N/AN/AN/AN/AN/A
LLIT
Lianluo Smart
N/AN/AN/AN/AN/A
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
3.01
3.01
Avinger, Inc. stock logo
AVGR
Avinger
N/A
0.63
0.36
Dynatronics Co. stock logo
DYNT
Dynatronics
0.21
1.41
0.67
LLIT
Lianluo Smart
N/A
2.42
2.17
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
4.84%
Avinger, Inc. stock logo
AVGR
Avinger
18.30%
Dynatronics Co. stock logo
DYNT
Dynatronics
4.18%
LLIT
Lianluo Smart
28.75%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
N/A

Insider Ownership

CompanyInsider Ownership
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
N/A
Avinger, Inc. stock logo
AVGR
Avinger
11.40%
Dynatronics Co. stock logo
DYNT
Dynatronics
9.10%
LLIT
Lianluo Smart
22.90%
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
85.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cellect Biotechnology Ltd. stock logo
APOP
Cellect Biotechnology
2,020977,000N/ANot Optionable
Avinger, Inc. stock logo
AVGR
Avinger
681.59 million1.41 millionNot Optionable
Dynatronics Co. stock logo
DYNT
Dynatronics
1544.88 million4.44 millionNot Optionable
LLIT
Lianluo Smart
62.21 millionN/ANot Optionable
Medite Cancer Diagnostics, Inc. stock logo
MDIT
Medite Cancer Diagnostics
69N/AN/ANot Optionable

AVGR, DYNT, APOP, MDIT, and LLIT Headlines

SourceHeadline
King Charless Cancer Diagnosis and Treatment TimelineKing Charles's Cancer Diagnosis and Treatment Timeline
townandcountrymag.com - April 29 at 5:05 PM
Cancer Diagnostics – Webinars and Online EventsCancer Diagnostics – Webinars and Online Events
technologynetworks.com - April 16 at 7:41 PM
A cancer diagnosis is a shock. Heres advice on how to share the newsA cancer diagnosis is a shock. Here's advice on how to share the news
kunm.org - March 30 at 9:45 AM
About Pancreatic CancerAbout Pancreatic Cancer
bcm.edu - March 14 at 11:35 PM
New Diagnostic Techniques for Breast Cancer DetectionNew Diagnostic Techniques for Breast Cancer Detection
medscape.com - February 8 at 10:38 AM
Targeted Optical Contrast Agents for Cancer DiagnosticsTargeted Optical Contrast Agents for Cancer Diagnostics
medscape.com - January 30 at 6:59 AM
Pancreatic Cancer Resource CenterPancreatic Cancer Resource Center
webmd.com - November 14 at 1:47 AM
Patient Navigation in Breast Cancer: A Systematic ReviewPatient Navigation in Breast Cancer: A Systematic Review
medscape.com - October 24 at 12:38 PM
Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’
finance.yahoo.com - September 26 at 8:58 AM
Cancer Diagnostics – ProductsCancer Diagnostics – Products
technologynetworks.com - September 11 at 5:24 AM
Pancreatic Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028Pancreatic Cancer Diagnostics Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028
finance.yahoo.com - September 2 at 7:03 AM
Breast Cancer Diagnostics Market to Grow Rapidly at a CAGR of 8.7% by 2030 | DataM IntelligenceBreast Cancer Diagnostics Market to Grow Rapidly at a CAGR of 8.7% by 2030 | DataM Intelligence
finance.yahoo.com - August 23 at 4:05 PM
Heres why some people keep their cancer diagnosis to themselves: An incredibly personal decisionHere's why some people keep their cancer diagnosis to themselves: 'An incredibly personal decision'
yahoo.com - August 18 at 3:18 AM
Cancer Diagnostics – News and FeaturesCancer Diagnostics – News and Features
technologynetworks.com - August 16 at 8:16 PM
Cancer DiagnosticsCancer Diagnostics
technologynetworks.com - August 16 at 3:15 PM
Simple blood test combined with risk model improves lung cancer mortality predictionSimple blood test combined with risk model improves lung cancer mortality prediction
news-medical.net - June 28 at 11:05 PM
A New Urine Test Could Be a Simple Way to Check For CancerA New Urine Test Could Be a Simple Way to Check For Cancer
msn.com - May 10 at 5:00 AM
Urine Test Could Reveal Cancer and MetastasesUrine Test Could Reveal Cancer and Metastases
medgadget.com - May 9 at 6:58 PM
Could you soon be testing for cancer in your own bathroom?Could you soon be testing for cancer in your own bathroom?
masslive.com - April 28 at 1:44 PM
Prostate CancerProstate Cancer
webmd.com - April 28 at 3:44 AM
MIT Unveils Simple Paper Test for Early Cancer DetectionMIT Unveils Simple Paper Test for Early Cancer Detection
scitechdaily.com - April 26 at 8:48 PM
Promising new AI can detect early signs of lung cancer that doctors cant seePromising new AI can detect early signs of lung cancer that doctors can't see
msn.com - April 11 at 9:05 PM
Integrating Next-Generation Sequencing Into Clinical Cancer DiagnosticsIntegrating Next-Generation Sequencing Into Clinical Cancer Diagnostics
medscape.com - April 11 at 11:03 AM
Exosomal MicroRNA: A Diagnostic Marker for Lung CancerExosomal MicroRNA: A Diagnostic Marker for Lung Cancer
medscape.com - April 2 at 1:36 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cellect Biotechnology logo

Cellect Biotechnology

NASDAQ:APOP
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
Avinger logo

Avinger

NASDAQ:AVGR
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.
Dynatronics logo

Dynatronics

NASDAQ:DYNT
Dynatronics Corporation, a medical device company, designs, manufactures, and sells physical therapy, rehabilitation, orthopedics, pain management, and athletic training products in the United States. The company offers orthopedic soft bracing products include cervical collars, shoulder immobilizers, arm slings, wrist and elbow supports, abdominal and lumbosacral supports, maternity supports, knee immobilizers and supports, ankle walkers and supports, plantar fasciitis splints, and cold therapy products. It also offers physical therapy and rehabilitation products, which include therapeutic modality devices comprising electrotherapy, ultrasound, phototherapy, traction, hot and cold therapy, and electrodes; and power and manually operated treatment tables, mat platforms, work tables, parallel bars, training stairs, weight racks, and other related equipment. In addition, the company manufactures and distributes clinical supplies, including exercise bands and tubing, lotions and gels, orthopedic bracings, paper products, and other related supplies. It markets its products under the Dynatron, Dynatron Solaris, Dynaheat, BodyIce, Powermatic, Bird & Cronin, Physician's Choice, Hausmann, PROTEAM, and Mammoth brands. The company sells its products to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, hospitals, and retail distributors and equipment manufacturers. It also exports its products in Asia, Latin America, and the Middle East. Dynatronics Corporation was founded in 1979 and is headquartered in Eagan, Minnesota.

Lianluo Smart

NASDAQ:LLIT
Lianluo Smart Limited, together with its subsidiaries, designs, develops, markets, and distributes medical products primarily in China and internationally. The company offers medical devices, including wearable sleep respiratory solutions, general hospital products, medical compressors, and related supporting products. It also provides technical services in relation to the detection and analysis of obstructive sleep apnea syndrome to hospitals and medical centers through medical wearable devices. In addition, the company distributes medical products, such as sleep apnea machines. Lianluo Smart Limited sells its products primarily through distributors; and directly to hospitals, physical examination centers, and sleep centers, as well as to individual consumers. The company was formerly known as Dehaier Medical Systems Limited and changed its name to Lianluo Smart Limited in November 2016. Lianluo Smart Limited was incorporated in 2003 and is headquartered in Beijing, China.
Medite Cancer Diagnostics logo

Medite Cancer Diagnostics

OTCMKTS:MDIT
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.